Exact Sciences shares dip after preliminary fourth-quarter report

Exact Sciences Corp.’s stock took a hit in trading on Monday even though the Madison maker of Cologuard reported preliminary results for the fourth quarter and the full 2017 fiscal year showing sharp increases in the use of its colorectal cancer DNA stool test.

Exact said it expects revenue for the fourth quarter, which ended Dec. 31, 2017, to be $86.9 million to $87.9 million, an increase of as much as 150 percent from its 2016 fourth-quarter revenue...

   ...more

Ken Notes: I remain a fan, when we start to reign in healthcare costs Cologuard DNA test are going to be the value standard....



- - Volume: 6 - WEEK: 2 Date: 1/11/2018 1:34:18 PM -